modelInterferonAlfaNatural
Extends from Pharmacolibrary.Drugs.ATC.L.L03AB01.
Information
| name: | InterferonAlfaNatural | |
| ATC code: | L03AB01 | route: | intramuscular |
| compartments: | 1 | |
| dosage: | 5 | mg |
| volume of distribution: | 0.25 | L |
| clearance: | 0.02 | L/h/kg |
| other parameters in model implementation | ||
Interferon alfa natural is a naturally occurring glycoprotein with antiviral, antiproliferative, and immunomodulatory activity. It is used mainly in the treatment of certain viral infections such as hepatitis B and C, and some malignancies like hairy cell leukemia, chronic myelogenous leukemia (CML), Kaposi's sarcoma and malignant melanoma. Its use has largely been replaced by recombinant forms of interferon in most countries, but it was previously an approved therapy.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult volunteers receiving intramuscular injection.
References
Niwakawa, M, et al., & Sumiyoshi, Y (2012). Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. Investigational new drugs 30(3) 1046–1054. DOI:10.1007/s10637-010-9630-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21246251
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)